METAP2 and Alzheimer disease: Neuroinflammation appears to play a primary role in AD pathogenesis by exacerbating Aβ burden and tau hyperphosphorylation [19,20], and it has been shown that MetAP2 inhibitors exert immunosuppressive properties [21], which have a strong correlation with antiangiogenic properties [22,23].